Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Neuropsychobiology ; 82(4): 220-233, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37321188

RESUMO

INTRODUCTION: Sleep disturbances are highly prevalent across most major psychiatric disorders. Alterations in the hypothalamic-pituitary-adrenal axis, neuroimmune mechanisms, and circadian rhythm disturbances partially explain this connection. The gut microbiome is also suspected to play a role in sleep regulation, and recent studies suggest that certain probiotics, prebiotics, synbiotics, and fecal microbiome transplantation can improve sleep quality. METHODS: We aimed to assess the relationship between gut-microbiota composition, psychiatric disorders, and sleep quality in this cross-sectional, cross-disorder study. We recruited 103 participants, 63 patients with psychiatric disorders (major depressive disorder [n = 31], bipolar disorder [n = 13], psychotic disorder [n = 19]) along with 40 healthy controls. Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI). The fecal microbiome was analyzed using 16S rRNA sequencing, and groups were compared based on alpha and beta diversity metrics, as well as differentially abundant species and genera. RESULTS: A transdiagnostic decrease in alpha diversity and differences in beta diversity indices were observed in psychiatric patients, compared to controls. Correlation analysis of diversity metrics and PSQI score showed no significance in the patient and control groups. However, three species, Ellagibacter isourolithinifaciens, Senegalimassilia faecalis, and uncultured Blautia sp., and two genera, Senegalimassilia and uncultured Muribaculaceae genus, were differentially abundant in psychiatric patients with good sleep quality (PSQI >8), compared to poor-sleep quality patients (PSQI ≤8). CONCLUSION: In conclusion, this study raises important questions about the interconnection of the gut microbiome and sleep disturbances.


Assuntos
Transtorno Depressivo Maior , Microbioma Gastrointestinal , Transtornos Mentais , Transtornos do Sono-Vigília , Humanos , Microbioma Gastrointestinal/genética , RNA Ribossômico 16S/genética , Estudos Transversais , Sistema Hipotálamo-Hipofisário , Sistema Hipófise-Suprarrenal , Transtornos Mentais/diagnóstico , Sono
2.
Toxicol In Vitro ; 60: 369-382, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31233786

RESUMO

A549 cells are common models in the assessment of respiratory cytotoxicity. To provide physiologically more representative exposure conditions and increase the differentiation state, respiratory cells, for instance Calu-3 bronchial epithelial cells, are cultured at an air-liquid interface (ALI). There are indications that A549 cells also change their phenotype upon culture in ALI. The influence of culture in two variations of transwell cultures compared to conventional culture in plastic wells on the phenotype of A549 cells was studied. Cells were characterized by morphology, proliferation and transepithelial electrical resistance, whole genome transcription analysis, Western blot and immunocytochemical detection of pro-surfactant proteins. Furthermore, lipid staining, surface morphology, cell elasticity, surface tension and reaction to quartz particles were performed. Relatively small changes were noted in the expression of differentiation markers for alveolar cells but A549 cells cultured in ALI showed marked differences in lipid staining and surface morphology, surface tension and cytotoxicity of quartz particles. Data show that changes in physiological reactions of A549 cells in ALI culture were rather caused by change of surface properties than by increased expression of surfactant proteins.


Assuntos
Técnicas de Cultura de Células , Células A549 , Ar , Sobrevivência Celular/efeitos dos fármacos , Humanos , Fenótipo , Proteínas Associadas a Surfactantes Pulmonares/metabolismo , Quartzo/toxicidade , Propriedades de Superfície
3.
Sci Rep ; 9(1): 2358, 2019 02 20.
Artigo em Inglês | MEDLINE | ID: mdl-30787385

RESUMO

Preclinical studies have demonstrated that the endocannabinoid system (ECS) plays an important role in the protection against intestinal inflammation and colorectal cancer (CRC); however, human data are scarce. We determined members of the ECS and related components of the 'endocannabinoidome' in patients with inflammatory bowel disease (IBD) and CRC, and compared them to control subjects. Anandamide (AEA) and oleoylethanolamide (OEA) were increased in plasma of ulcerative colitis (UC) and Crohn's disease (CD) patients while 2-arachidonoylglycerol (2-AG) was elevated in patients with CD, but not UC. 2-AG, but not AEA, PEA and OEA, was elevated in CRC patients. Lysophosphatidylinositol (LPI) 18:0 showed higher levels in patients with IBD than in control subjects whereas LPI 20:4 was elevated in both CRC and IBD. Gene expression in intestinal mucosal biopsies revealed different profiles in CD and UC. CD, but not UC patients, showed increased gene expression for the 2-AG synthesizing enzyme diacylglycerol lipase alpha. Transcripts of CNR1 and GPR119 were predominantly decreased in CD. Our data show altered plasma levels of endocannabinoids and endocannabinoid-like lipids in IBD and CRC and distinct transcript profiles in UC and CD. We also report alterations for less known components in intestinal inflammation, such as GPR119, OEA and LPI.


Assuntos
Neoplasias Colorretais/metabolismo , Endocanabinoides/metabolismo , Doenças Inflamatórias Intestinais/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Ácidos Araquidônicos/análise , Ácidos Araquidônicos/sangue , Colite Ulcerativa/metabolismo , Neoplasias do Colo/metabolismo , Neoplasias Colorretais/fisiopatologia , Doença de Crohn/metabolismo , Endocanabinoides/análise , Endocanabinoides/sangue , Feminino , Glicerídeos/análise , Glicerídeos/sangue , Humanos , Inflamação , Doenças Inflamatórias Intestinais/fisiopatologia , Masculino , Pessoa de Meia-Idade , Ácidos Oleicos/análise , Ácidos Oleicos/sangue , Alcamidas Poli-Insaturadas/análise , Alcamidas Poli-Insaturadas/sangue , Receptor CB1 de Canabinoide/metabolismo , Receptores Acoplados a Proteínas G/metabolismo
4.
Oncol Rep ; 31(3): 1147-56, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24378831

RESUMO

Osteosarcoma is a rare but aggressive bone neoplasm in humans, which is commonly treated with surgery, classical chemotherapy and radiation. Sorafenib, an inhibitor of a number of kinases targeting the Raf/MEK/ERK pathway, is a promising new chemotherapeutic agent in human medicine that has been approved since 2006 for the therapy of renal cell carcinoma and since 2007 for the treatment of hepatocellular carcinoma. Here, we studied the antimetastatic potential of 4 µM of this multikinase inhibitor in a human osteosarcoma cell line. DNA microarray-based gene expression profiling detected 297 and 232 genes upregulated or downregulated at a threshold of >2-fold expression alteration (P<0.05) in the sorafenib-treated cells. Three genes (CXCR4, FOS and S100A4) that are involved in tumor progression were chosen for validation by quantitative PCR (qPCR) and protein expression analysis. The decrease in RNA expression detected by microarray profiling was confirmed by qPCR for all three genes (P<0.01). On the protein level, sorafenib-induced reduction of S100A4 was verified both by western blotting and immunohistochemistry. For CXCR4 and c-Fos, a reduced protein expression was shown by immunohistochemistry, for c-Fos also by immunoblotting. We conclude that sorafenib could serve as a potent chemotherapeutical agent by which to inhibit the metastatic progression of osteosarcomas.


Assuntos
Antineoplásicos/farmacologia , Niacinamida/análogos & derivados , Proteínas Oncogênicas v-fos/metabolismo , Compostos de Fenilureia/farmacologia , Receptores CXCR4/metabolismo , Proteínas S100/metabolismo , Neoplasias Ósseas , Linhagem Celular Tumoral , Regulação para Baixo , Ensaios de Seleção de Medicamentos Antitumorais , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Niacinamida/farmacologia , Análise de Sequência com Séries de Oligonucleotídeos , Proteínas Oncogênicas v-fos/genética , Osteossarcoma , Receptores CXCR4/genética , Proteína A4 de Ligação a Cálcio da Família S100 , Proteínas S100/genética , Sorafenibe , Transcriptoma/efeitos dos fármacos
5.
BMC Cancer ; 14: 40, 2014 Jan 25.
Artigo em Inglês | MEDLINE | ID: mdl-24460801

RESUMO

BACKGROUND: Hypoxia-induced genes are potential targets in cancer therapy. Responses to hypoxia have been extensively studied in vitro, however, they may differ in vivo due to the specific tumor microenvironment. In this study gene expression profiles were obtained from fresh human lung cancer tissue fragments cultured ex vivo under different oxygen concentrations in order to study responses to hypoxia in a model that mimics human lung cancer in vivo. METHODS: Non-small cell lung cancer (NSCLC) fragments from altogether 70 patients were maintained ex vivo in normoxia or hypoxia in short-term culture. Viability, apoptosis rates and tissue hypoxia were assessed. Gene expression profiles were studied using Affymetrix GeneChip 1.0 ST microarrays. RESULTS: Apoptosis rates were comparable in normoxia and hypoxia despite different oxygenation levels, suggesting adaptation of tumor cells to hypoxia. Gene expression profiles in hypoxic compared to normoxic fragments largely overlapped with published hypoxia-signatures. While most of these genes were up-regulated by hypoxia also in NSCLC cell lines, membrane metallo-endopeptidase (MME, neprilysin, CD10) expression was not increased in hypoxia in NSCLC cell lines, but in carcinoma-associated fibroblasts isolated from non-small cell lung cancers. High MME expression was significantly associated with poor overall survival in 342 NSCLC patients in a meta-analysis of published microarray datasets. CONCLUSIONS: The novel ex vivo model allowed for the first time to analyze hypoxia-regulated gene expression in preserved human lung cancer tissue. Gene expression profiles in human hypoxic lung cancer tissue overlapped with hypoxia-signatures from cancer cell lines, however, the elastase MME was identified as a novel hypoxia-induced gene in lung cancer. Due to the lack of hypoxia effects on MME expression in NSCLC cell lines in contrast to carcinoma-associated fibroblasts, a direct up-regulation of stroma fibroblast MME expression under hypoxia might contribute to enhanced aggressiveness of hypoxic cancers.


Assuntos
Biomarcadores Tumorais/metabolismo , Carcinoma Pulmonar de Células não Pequenas/enzimologia , Fibroblastos/enzimologia , Neoplasias Pulmonares/enzimologia , Neprilisina/metabolismo , Células Estromais/enzimologia , Apoptose , Biomarcadores Tumorais/genética , Carcinoma Pulmonar de Células não Pequenas/genética , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Hipóxia Celular , Linhagem Celular Tumoral , Sobrevivência Celular , Fibroblastos/patologia , Perfilação da Expressão Gênica/métodos , Regulação Enzimológica da Expressão Gênica , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Neprilisina/genética , Análise de Sequência com Séries de Oligonucleotídeos , Células Estromais/patologia , Técnicas de Cultura de Tecidos , Regulação para Cima
6.
BMC Genomics ; 13: 594, 2012 Nov 05.
Artigo em Inglês | MEDLINE | ID: mdl-23127113

RESUMO

BACKGROUND: Reports on common mutations in neuroendocrine tumors (NET) are rare and clonality of NET metastases has not been investigated in this tumor entity yet. We selected one NET and the corresponding lymph node and liver metastases as well as the derivative cell lines to screen for somatic mutations in the primary NET and to track the fate of genetic changes during metastasis and in vitro progression. RESULTS: Applying microarray based sequence capture resequencing including 4,935 Exons from of 203 cancer-associated genes and high-resolution copy number and genotype analysis identified multiple somatic mutations in the primary NET, affecting BRCA2, CTNNB1, ERCC5, HNF1A, KIT, MLL, RB1, ROS1, SMAD4, and TP53. All mutations were confirmed in the patients' lymph node and liver metastasis tissue as well as early cell line passages. In contrast to the tumor derived cell line, higher passages of the metastases derived cell lines lacked somatic mutations and chromosomal alterations, while expression of the classical NET marker serotonin was maintained. CONCLUSION: Our study reveals that both metastases have evolved from the same pair of genetically differing NET cell clones. In both metastases, the in vivo dominating "mutant" tumor cell clone has undergone negative selection in vitro being replaced by the "non-mutant" tumor cell population. This is the first report of a bi-clonal origin of NET derived metastases, indicating selective advantage of interclonal cooperation during metastasis. In addition, this study underscores the importance to monitor cell line integrity using high-resolution genome analysis tools.


Assuntos
Neoplasias Hepáticas/genética , Metástase Linfática/genética , Tumores Neuroendócrinos/genética , Linhagem Celular Tumoral , Cromossomos/genética , Cromossomos/metabolismo , Variações do Número de Cópias de DNA , Éxons , Genótipo , Humanos , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/secundário , Mutação , Tumores Neuroendócrinos/metabolismo , Tumores Neuroendócrinos/patologia , Polimorfismo de Nucleotídeo Único , Análise de Sequência de DNA , Serotonina/genética , Serotonina/metabolismo , Proteína Supressora de Tumor p53/genética , Proteína Supressora de Tumor p53/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA